The mumps vaccine is a preventive measure against mumps, a contagious viral infection caused by the mumps virus. The vaccine is commonly administered as part of the measles, mumps, and rubella (MMR) vaccine or the measles, mumps, rubella, and varicella (MMRV) vaccine. The mumps vaccine provides immunity against the mumps virus, which can lead to swollen salivary glands, fever, and other complications. Vaccination typically occurs in childhood, with a two-dose schedule recommended for optimal protection. Vaccination efforts have significantly reduced the incidence of mumps and related complications, such as meningitis and orchitis. However, occasional outbreaks still occur, emphasizing the importance of maintaining high vaccine coverage. The mumps vaccine contributes to herd immunity, protecting both vaccinated individuals and those unable to receive the vaccine due to medical reasons. Continuous surveillance, public awareness, and global vaccination initiatives remain essential to preventing mumps and its potential complications.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States